title: Radiotherapy after prostatectomy.
abstract: OBJECTIVE
  The role of radiotherapy after prostatectomy is controversial. This paper tries to give some guidelines for everyday practice through an analysis of literature data.
  
  
  METHODS
  The potential role of radiotherapy in the adjuvant and salvage setting is discussed. We also report and interpret available literature data for both settings.
  
  
  RESULTS
  As regards an increase in or detectable prostate-specific antigen (PSA) after radical prostatectomy, about 40-50% of patients are rendered bNED with local salvage radiotherapy, but only 10-50% are long-term (5 years) biochemically controlled. A timely salvage treatment is crucial to optimize control probability. As regards adjuvant radiotherapy for undetectable postoperative PSA in patients at high risk of failure as judged on pathology, results are more encouraging. Recent data report bNED rates > 70% at 5 years.
  
  
  CONCLUSIONS
  Although results are far from satisfactory, salvage radiotherapy should be considered for every patient with an increased or detectable PSA after surgery. Adjuvant radiotherapy seems preferable to salvage radiotherapy for patients at high (> 30%) risk of failure.
authors.affiliation: Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX 77555-0711, USA. gisangui@utmb.edu
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Sanguineti
authors.forename: Paola
authors.initials: P
authors.lastname: Franzone
authors.forename: Laura
authors.initials: L
authors.lastname: Culp
authors.forename: Michela
authors.initials: M
authors.lastname: Marcenaro
authors.forename: Salvina
authors.initials: S
authors.lastname: Barra
authors.forename: Vito
authors.initials: V
authors.lastname: Vitale
mesh_terms: D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000276:immunology / Q000532:radiotherapy* / Q000601:surgery; D018714:Radiotherapy, Adjuvant; D016879:Salvage Therapy / Q000379:methods*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen